Cargando…
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
BACKGROUND: Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizum...
Autores principales: | De Rossi, Nicola, Scarpazza, Cristina, Filippini, Chiara, Cordioli, Cinzia, Rasia, Sarah, Mancinelli, Chiara Rosa, Rizzoni, Damiano, Romanelli, Giuseppe, Cossi, Stefania, Vettoretto, Nereo, Bove, Sergio, Manfredini, Silvano, Beindorf, Eva Andrea, Mosca, Carlo, Scipione, Vittorio, Flamminio, Gigliola, Albini, Elena Albini, Giansiracusa, Paola, Capra, Ruggero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366117/ https://www.ncbi.nlm.nih.gov/pubmed/32838235 http://dx.doi.org/10.1016/j.eclinm.2020.100459 |
Ejemplares similares
-
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
por: Capra, Ruggero, et al.
Publicado: (2020) -
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings
por: Mattioli, Flavia, et al.
Publicado: (2015) -
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021) -
Single port laparoscopic appendectomy: are we pursuing real advantages?
por: Vettoretto, Nereo, et al.
Publicado: (2011) -
COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment
por: Muccioli, Lorenzo, et al.
Publicado: (2020)